Novo Nordisk partners with Hengrui Pharma in a deal potentially worth up to $2.6 billion, introducing a new weekly oral treatment option for obesity into its pipeline. This collaboration aims to enhance Novo's offerings in the obesity market.
Investors looking for more transformative business development at Novo will have to wait, but a new partnership with China’s Hengrui Pharma adds a new weekly oral option to the Danish pharma’s early pipeline.
Original title: “Novo adds long-term obesity differentiation in up to $2.6B Hengrui deal”